Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- AF812 - Provider product page
- Provider
- Novus Biologicals
- Product name
- Goat Polyclonal Flt-3/Flk-2/CD135 Antibody
- Antibody type
- Polyclonal
- Description
- Immunogen affinity purified. Detects human Flt-3/Flk-2 in direct ELISAs and Western blots. In direct ELISAs, approximately 35% cross-reactivity with recombinant mouse Flt-3 is observed.
- Reactivity
- Human
- Host
- Goat
- Isotype
- IgG
- Vial size
- 100 ug
- Concentration
- LYOPH
- Storage
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.
Submitted references Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML).
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.
Ravandi F, Jilani I, Estey E, Kantarjian H, Dey A, Aguilar C, Jitkaroon C, Giles F, O'Brien S, Keating M, Albitar M
Leukemia research 2007 Jun;31(6):791-7
Leukemia research 2007 Jun;31(6):791-7
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.
Armstrong SA, Kung AL, Mabon ME, Silverman LB, Stam RW, Den Boer ML, Pieters R, Kersey JH, Sallan SE, Fletcher JA, Golub TR, Griffin JD, Korsmeyer SJ
Cancer cell 2003 Feb;3(2):173-83
Cancer cell 2003 Feb;3(2):173-83
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.
Armstrong SA, Kung AL, Mabon ME, Silverman LB, Stam RW, Den Boer ML, Pieters R, Kersey JH, Sallan SE, Fletcher JA, Golub TR, Griffin JD, Korsmeyer SJ
Cancer cell 2003 Feb;3(2):173-83
Cancer cell 2003 Feb;3(2):173-83
No comments: Submit comment
No validations: Submit validation data